Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study

Although the direct oral anticoagulant rivaroxaban is recommended for stroke prevention in patients with non-valvular atrial fibrillation based on Phase III clinical trials, there is still a need for additional safety data from everyday clinical practice. The ROSE study was initiated to collect furt...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	PloS one Ročník 15; číslo 10; s. e0240489
Hlavní autoři:	Evans, Alison, Davies, Miranda, Osborne, Vicki, Roy, Debabrata, Shakir, Saad
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Public Library of Science 09.10.2020 Public Library of Science (PLoS)
Témata:	Administration, Oral Aged Aged, 80 and over Anticoagulants Atrial fibrillation Atrial Fibrillation - drug therapy Bleeding Cardiac arrhythmia Clinical trials Diabetes Disease prevention Drug dosages Drug therapy Embolisms England - epidemiology Factor Xa Inhibitors - administration & dosage Factor Xa Inhibitors - adverse effects Female Fibrillation Health risks Hemorrhage Hemorrhage - chemically induced Hemorrhage - epidemiology Humans Hypertension Incidence Male Medical records Medical research Medicine and Health Sciences Patient outcomes Patients Prevention Primary care Product safety Questionnaires Risk Risk factors Rivaroxaban Rivaroxaban - administration & dosage Rivaroxaban - adverse effects Safety Safety research Secondary Care Stroke Stroke - prevention & control Thrombosis Wales - epidemiology England Wales United Kingdom United Kingdom > UK
ISSN:	1932-6203, 1932-6203
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!